pte20260309001 in Leben
Body’s Natural Healing Process Enhanced – ANP Hormone Takes Key Role
|
Heart: Help for the infarcted pump organ (OpenClipart-Vectors, pixabay.com) |
New York/Oxford/College Station (pte001/03.09.2026/06:00)
A new therapy developed by researchers at Columbia University, Texas A&M University, and the University of Oxford may reduce the consequences of a heart attack by bolstering the body’s own healing abilities. Following a heart attack, the body releases a hormone called atrial natriuretic peptide, or ANP, which helps reduce stress on the heart and limit long-term damage. Although, the amount the body produces is often insufficient to significantly improve recovery.
Supporting Repair
The new therapy involves an injection that instructs the body to produce additional ANP for a specific period. The hormone then travels through the bloodstream to the heart, where it helps reduce stress and support repair processes. This research offers a potential new approach to cardiac care, as heart disease remains a leading cause of death globally.
“Essentially, this is an amplification of the body’s own protective system for the heart,” says Ke Huang, an assistant professor of pharmacy at the Texas university. “The body already uses ANP. We are simply helping it produce enough during a critical phase of healing.”
A Path to a Strengthened Heart
Even if patients survive the initial heart attack, the heart often weakens over time due to scar tissue formation and the loss of healthy tissue. Current therapies are unable to fully prevent this long-term decline. “Our goal is to protect the heart precisely when it is most vulnerable. By alleviating this early stress and supporting repair, we may be able to improve patient recovery,” researchers explained.
Huang believes that by providing additional support to the heart during the recovery phase, scar tissue formation will be reduced, healthy heart muscle will be preserved, the heart’s pumping function will improve, and the risk of long-term complications will decrease. The team will continue to investigate the safety of the procedure, as well as optimize the timing and dosage, before clinical trials in humans begin.
(Ende)
